News
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25 ...
--BioArctic AB's partner Eisai today announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reaffirmed its positive opinion for the anti-Aβ ...
Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk ...
The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
8d
InvestorsHub on MSNPositive CHMP Opinion for Gilead’s Lenacapavir in HIV PreventionGilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...
IntraBio Inc., a biopharmaceutical company focused on developing therapies for rare neurological diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products ...
KalVista on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers Ekterly in people ages 12 and older for the symptomatic treatment of ...
TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025/ PRNewswire/-- Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency ...
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU Provided by PR Newswire Feb 28, 2025 5:11am ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results